Mean platelet volume in patients with rheumatoid arthritis: the effect of anti-TNF-α therapy
Research output: Contribution to journal › Article › peer-review
Standard Standard
In: Rheumatology international, Vol. 30, No. 8, 06.2010, p. 1125-9.
Research output: Contribution to journal › Article › peer-review
HarvardHarvard
APA
CBE
MLA
VancouverVancouver
Author
RIS
TY - JOUR
T1 - Mean platelet volume in patients with rheumatoid arthritis
T2 - the effect of anti-TNF-α therapy
AU - Gasparyan, Armen Yuri
AU - Sandoo, Aamer
AU - Stavropoulos-Kalinoglou, Antonios
AU - Kitas, George D
PY - 2010/6
Y1 - 2010/6
N2 - A number of mediators are involved in the inflammatory processes that affect joints and vascular wall of patients with rheumatoid arthritis (RA). Tumour necrosis factor alpha (TNFa) is one such mediator, and it is widely regarded as an important target for anti-rheumatic treatment. Most recent studies show that anti-TNFa medication suppresses inflammation and reduces overall activity of RA. The aim of the current study was to investigate changes of mean platelet volume (MPV) in response to the 3-month anti-TNFa therapy in RA. Twenty-one RA patients without established cardiovascular disease were recruited for anti-TNFa therapy and underwent thorough clinical and laboratory evaluation at baseline, 2 weeks, and 12 weeks. Anti-TNFa therapy resulted in a significant (p = 0.01) increase in MPV over the duration of the study (7.7 +/- 0.9, 7.8 +/- 1.1, and 8.4 +/- 1.1 fL at baseline, 2 weeks, and 12 weeks, respectively). The results of the study expand perspectives of the use of MPV in conditions associated with high-grade inflammation, particularly RA, for monitoring anti-inflammatory treatment. More prospective studies with large numbers of patients are warranted to ascertain associations of high and low values of MPV with diverse markers of inflammation and vascular pathology.
AB - A number of mediators are involved in the inflammatory processes that affect joints and vascular wall of patients with rheumatoid arthritis (RA). Tumour necrosis factor alpha (TNFa) is one such mediator, and it is widely regarded as an important target for anti-rheumatic treatment. Most recent studies show that anti-TNFa medication suppresses inflammation and reduces overall activity of RA. The aim of the current study was to investigate changes of mean platelet volume (MPV) in response to the 3-month anti-TNFa therapy in RA. Twenty-one RA patients without established cardiovascular disease were recruited for anti-TNFa therapy and underwent thorough clinical and laboratory evaluation at baseline, 2 weeks, and 12 weeks. Anti-TNFa therapy resulted in a significant (p = 0.01) increase in MPV over the duration of the study (7.7 +/- 0.9, 7.8 +/- 1.1, and 8.4 +/- 1.1 fL at baseline, 2 weeks, and 12 weeks, respectively). The results of the study expand perspectives of the use of MPV in conditions associated with high-grade inflammation, particularly RA, for monitoring anti-inflammatory treatment. More prospective studies with large numbers of patients are warranted to ascertain associations of high and low values of MPV with diverse markers of inflammation and vascular pathology.
KW - Aged
KW - Arthritis, Rheumatoid
KW - Blood Platelets
KW - Blood Sedimentation
KW - Female
KW - Humans
KW - Immunosuppressive Agents
KW - Male
KW - Middle Aged
KW - Platelet Count
KW - Treatment Outcome
KW - Tumor Necrosis Factor-alpha
KW - Journal Article
U2 - 10.1007/s00296-009-1345-1
DO - 10.1007/s00296-009-1345-1
M3 - Article
C2 - 20066426
VL - 30
SP - 1125
EP - 1129
JO - Rheumatology international
JF - Rheumatology international
SN - 0172-8172
IS - 8
ER -